National Multiple Sclerosis Society (NMSS)

eSupport Health was established in November 2019, as a Delaware Public Benefit Corporation, to provide practical, actionable solutions that improve mental health for people living with MS and other chronic conditions. The company currently offers professional support groups for (1) people living with MS, (2) people newly diagnosed with MS, and (3) loved ones and family members of people living with MS. Groups meet weekly via secure online video and are moderated by experienced coaches who are licensed therapists with MS expertise. The first month is free of charge. eSupport Health also offers free monthly workshops, open to everyone who registers.

BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD). NurOwn™, our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases. We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of neuron cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation. The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval. On February 2011, NurOwn was granted Orphan Drug designation by the FDA. Over 20 publications in leading scientific journals demonstrating neuron mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team.

Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. The company innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.

Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.